Trial site
Szpital Uniwersytecki Nr 1 Im. Dr. A. Jurasza W Bydgoszczy
Bydgoszcz, 85-094, PolandEU-13 widening countryNot linked to an institution yet
- 14running trials
- 9closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 44 trials
- Phase 12 trials
- Phase 2/32 trials
- Phase 21 trial
- Status
- Completed9 trials
- Active, not recruiting8 trials
- Recruiting5 trials
- Suspended2 trials
- Not yet recruiting1 trial
- Lead sponsor
- AstraZeneca2 trials
- GPOH gGmbH2 trials
- Janssen Research & Development, LLC2 trials
- Medical University Of Gdansk2 trials
- Medical University Of Lodz2 trials
- and 14 more
Running trials
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
NCT07195149· Phase 3· Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.· Source
Recruiting
BOOSTER – Multicenter, Open Label, Randomized Control Phase III Trial Comparing the Efficacy and Safety of Two Rituximab Regimens in Maintenance Therapy for Relapsing Nephrotic Syndrome Due to Podocytopathies in Adults.
(B cell Depletion Therapy to Improve Outcomes of Relapsing STERoid-sensitive Podocytopathies in Adults – BOOSTER trial)
2023-509755-13-00· Phase 3· Medical University Of Lodz· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway.
2024-518316-39-00· Phase 2/3· Medical University Of Lodz· Source
Active, not recruiting
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines
2023-505739-12-01· Phase 3· Novartis Pharma AG· Source
Active, not recruiting
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT04924608· Phase 3· AstraZeneca· Source
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source
Active, not recruiting
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
NCT05101148· Phase 1· AstraZeneca· Source
Active, not recruiting
AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia -
A randomized phase III study conducted in agreement with the AIEOP-BFM study group
2024-517253-27-00· Phase 3· Medical University Of Silesia Katowice Poland· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
NCT04629248· Phase 3· Hoffmann-La Roche· Source
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· Phase 3· University Hospital Muenster· Source
Active, not recruiting
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· Phase 3· Children's Oncology Group· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error